Evidence map›Paper›PMID 40638239›Full record

ArticleThe Journal of clinical investigation2025

Gut-specific histamine 3 receptor signaling orchestrates microglia-dependent resolution of peripheral inflammation.

Kerstin Dürholz, Leona Ehnes, Mathias Linnerbauer, Eva Schmid, Heike Danzer, Michael Hinzpeter-Schmidt, Lena Lößlein, Lena Amend, Michael Frech, Vugar Azizov and 25 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Kerstin DürholzDepartment of Internal Medicine 3, Rheumatology and Immunology.
Leona EhnesDepartment of Internal Medicine 3, Rheumatology and Immunology.
Mathias LinnerbauerDeutsches Zentrum Immuntherapie (DZI), and.
Eva SchmidDepartment of Internal Medicine 3, Rheumatology and Immunology.
Heike DanzerDepartment of Internal Medicine 3, Rheumatology and Immunology.
Michael Hinzpeter-SchmidtDepartment of Internal Medicine 3, Rheumatology and Immunology.
Lena LößleinDepartment of Neurology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Lena AmendDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany; Hannover Medical School, Hannover, Germany.
Michael FrechDepartment of Internal Medicine 3, Rheumatology and Immunology.
Vugar AzizovDepartment of Internal Medicine 3, Rheumatology and Immunology.
Fabian SchälterDepartment of Internal Medicine 3, Rheumatology and Immunology.
Arne GessnerInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Sébastien LucasDepartment of Internal Medicine 3, Rheumatology and Immunology.
Till-Robin LeskerDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany; Hannover Medical School, Hannover, Germany.
R Verena TaudteInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Jörg HofmannDepartment of Biology, Division of Biochemistry, Friedrich-Alexander University, Erlangen, Germany.
Felix BeyerInstitute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Hadar Bootz-MaozThe Goodman Faculty of Life Sciences, and Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, Israel.
Yasmin ReichThe Goodman Faculty of Life Sciences, and Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, Israel.
Hadar RomanoThe Goodman Faculty of Life Sciences, and Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, Israel.
Daniele MauroDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli," Naples, Italy.
Ruth BeckervordersandforthInstitute of Biochemistry, Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany.
Maja Skov KragsnaesDepartment of Rheumatology, Odense University Hospital, Odense, Denmark.
Torkell EllingsenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.
Wei XiangDepartment of Molecular Neurology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany.
Aiden HaghikiaDepartment of Molecular Cell Biology, Institute of Biochemistry and Pathobiochemistry, Ruhr University Bochum, Bochum, Germany.
Cezmi A AkdisSwiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.
Francesco CicciaDepartment of Precision Medicine, University of Campania "Luigi Vanvitelli," Naples, Italy.
Tobias BäuerleRadiologisches Institut, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Kerstin SarterDepartment of Internal Medicine 3, Rheumatology and Immunology.
Till StrowigDepartment of Microbial Immune Regulation, Helmholtz Centre for Infection Research, Braunschweig, Germany; Hannover Medical School, Hannover, Germany.
Nissan YissacharThe Goodman Faculty of Life Sciences, and Bar-Ilan Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat-Gan, Israel.
Georg SchettDepartment of Internal Medicine 3, Rheumatology and Immunology.
Veit RothhammerDeutsches Zentrum Immuntherapie (DZI), and.
Mario M ZaissDepartment of Internal Medicine 3, Rheumatology and Immunology.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammatory diseases like rheumatoid arthritis (RA) have been described to cause CNS activation. Less is known about environmental factors that enable the CNS to suppress peripheral inflammation in RA. Here, we identified gut microbiota-derived histamine as such a factor. We showed that low levels of histamine activate the enteric nervous system, increase inhibitory neurotransmitter concentrations in the spinal cord, and restore homeostatic microglia, thereby reducing inflammation in the joints. We found that elective histamine 3 receptor (H3R) signaling in the intestine was critical for this effect, as systemic and intrathecal application did not show effects. Microglia depletion or pharmacological silencing of local nerve fibers impaired oral H3R agonist-induced pro-resolving effects on arthritis. Moreover, therapeutic supplementation of the short-chain fatty acid propionate revealed one way to expand local intestinal histamine concentrations in mice and humans. Thus, we define a gut/CNS/joint axis pathway where microbiota-derived histamine initiates the resolution of arthritis via the CNS.

Indexed as

Arthritis, RheumatoidGastrointestinal MicrobiomeInflammationMicrogliaReceptors, Histamine H3Signal TransductionAnimalsHistamineHumansMaleMiceMice, KnockoutHistamineReceptors, Histamine H3Autoimmune diseasesAutoimmunityImmunologyRheumatology

Identifiers

PMID40638239
PMCPMC12435854

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.